Liraglutide CAS NO.204656-20-2

Liraglutide (NN2211) is a derivative of human incretin (metabolic hormone) glucagon-like peptide-1 (GLP-1) that is used as a long-acting glucagon-like peptide-1 receptor agonist, binding to the same receptors as does the endogenous metabolic hormone GLP-1 that stimulates insulin secretion. Marketed under the brand name Victoza, it is an injectable drug developed by Novo Nordisk for the treatment of type 2 diabetes. In 2015, Novo Nordisk began marketing a separate strength in the U.S. and E.U. under the brand name Saxenda as a treatment for adults who are obese or overweight with at least one weight-related comorbid condition.

The product was approved for treatment of type 2 diabetes by the European Medicines Agency (EMA) on July 3, 2009, and by the U.S. Food and Drug Administration (FDA) on January 25, 2010. More recently, Liraglutide was approved by the FDA on December 23, 2014 and by the European Medicines Agency on January 23, 2015, for adults with a body mass index (BMI) of 30 or greater (obesity) or a BMI of 27 or greater (overweight) who have at least one weight-related condition.

Senova means "Serve Innovation", we are a professional company who's supplying APIs(mainly New Generics), Advanced Intermediates and KSM(Key Starting Materials) & Peptides products combine technical Support/Registration support/Custom synthesis service(CMO) in pharmaceutical and related field , we focus on serving those manufacturers' New Generics Projects from R&D stage to Commercial Stage from meterials to documents support(DMF/CMC). For those regulated markets, we supply products under GMP regulation with Full Documentation(DMF and CMC).

Senova Main Products Includes ~ 

1. Anti-Cancer (Oncology) Series 

2. Anti-Infection Series 

3. Anti-Diabetes Series 

4. Pepties Series and other series

Senova Service Includes ~ 

1. Documents(CMD & DMF) for Registration 

2. Pre-Audit Service 

3. GMP Regulation Consultant 

Senova R&D center (pictures) ~ 

Sonova Factory(GMP LIKE and GMP regulation)